Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 534
- Registration Number
- NCT06600009
- Locations
- 🇯🇵
Novartis Pharma K.K., Tokyo, Japan
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 336
- Registration Number
- NCT06398652
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06331312
- Locations
- 🇺🇸
Accurate Clinical Research Inc, San Antonio, Texas, United States
🇺🇸Clinical Research Institute of Michigan LLC, Saint Clair Shores, Michigan, United States
🇨🇭Novartis Investigative Site, St Gallen, Switzerland
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT06130540
- Locations
- 🇺🇸
Houston Rheumatology & Arthrit, Katy, Texas, United States
🇺🇸Accurate Clinical Research Inc, San Antonio, Texas, United States
🇺🇸Overlake Internal Med Associates, Bellevue, Washington, United States
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05758415
- Locations
- 🇺🇸
Medvin Clinical Research, Van Nuys, California, United States
🇺🇸Horizon Clinical Research, La Mesa, California, United States
🇺🇸Conquest Research, Winter Park, Florida, United States
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- Conditions
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT05722522
- Locations
- 🇺🇸
Healthy Life Research, Miami, Florida, United States
🇺🇸Millennium Clinical Trials, Westlake Village, California, United States
🇺🇸Integral Rheumatology and Immunology Specialists IRIS, Plantation, Florida, United States
Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 758
- Registration Number
- NCT05677542
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Spain
Secukinumab in Active Non-segmental Vitiligo
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 8
- Registration Number
- NCT05676333
- Locations
- 🇧🇪
Department of Dermatology, Ghent University Hospital, Gent, Oost-Vlaanderen, Belgium
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 163
- Registration Number
- NCT05650060
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 340
- Registration Number
- NCT05622708
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.